Company intelligence / Profile preview
HepaLife BioSystems
Boston, MA, USAhepalife.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HepaLife BioSystems was a biotechnology company dedicated to the development of cell-based therapies and medical devices for the treatment of liver disease. Its flagship product, the HepaDrive, was a bio-artificial liver (BAL) system intended to provide extracorporeal support for patients suffering from acute liver failure. The technology utilized the proprietary HepaRG cell line, which mimics the metabolic functions of primary human hepatocytes. Although the company made progress in clinical development, it transitioned its business model and merged with Alliqua in 2010. Following the merger, the entity shifted its focus toward advanced wound care and drug delivery technologies.
- Therapeutic areas
- Gastroenterology
- Modalities
- DeviceCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
INSERM
Beyond the preview
Go deeper on HepaLife BioSystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HepaLife BioSystems.